Northern Trust Corp Lowers Stock Holdings in Elanco Animal Health Incorporated $ELAN

Northern Trust Corp lowered its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 1.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,915,690 shares of the company’s stock after selling 27,996 shares during the quarter. Northern Trust Corp owned about 0.59% of Elanco Animal Health worth $30,615,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Allworth Financial LP grew its holdings in shares of Elanco Animal Health by 791.7% during the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after buying an additional 2,090 shares during the last quarter. CoreCap Advisors LLC purchased a new stake in Elanco Animal Health in the 4th quarter valued at approximately $29,000. Parallel Advisors LLC boosted its holdings in Elanco Animal Health by 92.2% in the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock valued at $41,000 after purchasing an additional 1,852 shares in the last quarter. NBC Securities Inc. purchased a new stake in Elanco Animal Health in the 1st quarter valued at approximately $40,000. Finally, Versant Capital Management Inc boosted its holdings in Elanco Animal Health by 65.9% in the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company’s stock valued at $46,000 after purchasing an additional 1,740 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

ELAN stock opened at $18.38 on Friday. The firm has a 50 day moving average of $15.55 and a 200-day moving average of $12.70. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $18.87. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. The company has a market cap of $9.13 billion, a price-to-earnings ratio of 21.37, a PEG ratio of 3.41 and a beta of 1.66.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same period last year, the firm earned $0.30 EPS. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on ELAN. Zacks Research lowered Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. William Blair raised Elanco Animal Health from a “market perform” rating to an “outperform” rating in a report on Thursday, June 26th. Leerink Partners raised Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price objective on the stock in a report on Thursday, July 17th. Piper Sandler lifted their price objective on Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, August 11th. Finally, UBS Group lifted their price objective on Elanco Animal Health from $18.00 to $19.00 and gave the company a “buy” rating in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Elanco Animal Health has an average rating of “Moderate Buy” and an average price target of $17.33.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.